Posted by Michael Wonder on 02 Feb 2026
Call for access to improve quality of life for thyroid cancer survivors
2 February 2026 - A TGA approved drug that prevents kidney failure in thyroid cancer survivors remains inaccessible.
Thyroid cancer survivors are becoming increasingly frustrated that they cannot access a drug that prevents kidney failure, despite it being approved by the TGA for nearly a year.
Yorvipath is a treatment that replaces the missing hormone in chronic hypoparathyroidism, a condition that affects thousands of Australians, mostly after thyroid cancer treatment.
The TGA approved it in February 2025, however the PBAC has since rejected it twice, which means it cannot be listed on the PBS.
